Inching Toward Emergency Use Listing By WHO For Covaxin: Bharat Biotech

The Emergency Use Listing process is a step closer to the final decision on Covaxin's global acceptance as the rolling data is slated to begin next month, Bharat Biotech's Suchitra Ella said.

Emergency Use Listing (EUL) of Bharat Biotech's COVID-19 vaccine Covaxin by the World Health Organisation (WHO) is not a long drawn process as a majority of the vaccine makers' facilities have been audited by the global health body, Suchitra Ella, joint managing director of Bharat Biotech, said today. Our vision seldom changes course, until our final mission is accomplished #Covaxin .We ensure to take forward WHO EUL process as per the universal regulatory guidelines & timelines for covid 19 vaccines. We will keep you posted every step ahead 👍🏼😷💉🇮🇳🙏🏼 pic.twitter.com/ePs1zj1vlk "We are working closely with the World Health Organisation for the inclusion of Covaxin in its Emergency Use Listing. Approval from WHO is not expected to be a long drawn process as cell line and majority of our facilities have already been audited and approved by WHO for our other vaccines in the past," Ms Ella said in a tweet. She further said the EUL process is a step closer to the final decision on Covaxin's global acceptance as the rolling data is slated to begin next month.